Chemomab Therapeutics Ltd. (CMMB)

0.8390 +0.0290 (+3.58%) At close: 04:00PM EDT

Chemomab Therapeutics Ltd.

Building 7
Kiryat Atidim
Tel Aviv 6158002
Israel
972 77 331 0156
https://www.chemomab.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, CEO & Executive Director	330k	N/A	1982
Ms. Sigal Fattal CPA, M.B.A.	Chief Financial Officer	322k	N/A	1971
Dr. Matthew B. Frankel M.B.A., M.D.	Chief Medical Officer & VP of Drug Development	850k	N/A	1969
Barbara Lindheim	Consulting Vice President of Investor & Public Relations, Strategic Communications	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Corporate Governance

Chemomab Therapeutics Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.